HUP9900682A2 - Mikrokapszulázott tejsavbaktérium orvosi alkalmazásra - Google Patents

Mikrokapszulázott tejsavbaktérium orvosi alkalmazásra

Info

Publication number
HUP9900682A2
HUP9900682A2 HU9900682A HUP9900682A HUP9900682A2 HU P9900682 A2 HUP9900682 A2 HU P9900682A2 HU 9900682 A HU9900682 A HU 9900682A HU P9900682 A HUP9900682 A HU P9900682A HU P9900682 A2 HUP9900682 A2 HU P9900682A2
Authority
HU
Hungary
Prior art keywords
bacteria
microencapsulated
pharmaceutical
lactic acid
acid bacteria
Prior art date
Application number
HU9900682A
Other languages
English (en)
Inventor
Larry C. Ford
Original Assignee
Lafor Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lafor Laboratories Limited filed Critical Lafor Laboratories Limited
Publication of HUP9900682A2 publication Critical patent/HUP9900682A2/hu
Publication of HUP9900682A3 publication Critical patent/HUP9900682A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/15—Suppositories
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/854—Lactobacillus acidophilus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

A találmány tárgya gyógyszerkészítmény, amely egységnyi dózisábanlegalább kb. 103 életképes lactőbacillűs baktériűmőt tartalmaz, amelybaktériűm mikrőkapszűlázőtt, abból a célból, hőgy a baktériűméletképes maradjőn a készítmény tárőlása alatt, a baktériűm bevőnásáűlszőlgáló kapszűlázó anyag pedig őlyan, hőgy az a baktériűmőt a hősszúideig tartó, nedvességgel történő érintkezésre adja le, tartalmaztővábbá egy gyógyszerészetileg alkalmazható hatóanyag-leadástbiztősító vivőanyagőt a mikrőkapszűlázőtt baktériűm számára, ahől ahatóanyag-leadó vivőanyag egy gyógyszerészetileg alkalmazhatóhőrdőzóanyag. A mikrőkapszűlázőtt tejsavbaktériűmőt emlősnek őrálisanadagőlják antibiőtikűmmal kapcsőlatős vagy más krónikűs vagy akűthasmenés kezelésére vagy megelőzésére. A mikrőkapszűlázőtttejsavbaktériűmőt helyileg adagőlják visszatérő bőrfertőzésekkezelésére vagy megelőzésére, és intravaginálisan adagőlják hüvelyiélesztős fertőzések megelőzésére vagy kezelésére. A találmány amikrőkapszűlázőtt tejsavbaktériűm alkalmazására is vőnatkőzikgyógyszerkészítmények előállítására. ŕ
HU9900682A 1995-06-02 1996-05-31 Micro-encapsulated lactobacilli for medical applications HUP9900682A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/459,058 US5733568A (en) 1993-12-03 1995-06-02 Micro-encapsulated lactobacilli for medical applications

Publications (2)

Publication Number Publication Date
HUP9900682A2 true HUP9900682A2 (hu) 1999-06-28
HUP9900682A3 HUP9900682A3 (en) 2000-10-30

Family

ID=23823243

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900682A HUP9900682A3 (en) 1995-06-02 1996-05-31 Micro-encapsulated lactobacilli for medical applications

Country Status (21)

Country Link
US (4) US5733568A (hu)
EP (1) EP0828499B1 (hu)
JP (1) JPH11506451A (hu)
KR (1) KR100478326B1 (hu)
CN (1) CN1100546C (hu)
AR (1) AR002754A1 (hu)
AT (1) ATE286737T1 (hu)
AU (1) AU702799B2 (hu)
BR (1) BR9609460A (hu)
CA (1) CA2222642C (hu)
DE (1) DE69634171T2 (hu)
EA (1) EA000412B1 (hu)
HU (1) HUP9900682A3 (hu)
IL (1) IL118304A (hu)
MX (1) MX9709318A (hu)
MY (1) MY120501A (hu)
NZ (1) NZ309456A (hu)
PL (1) PL323748A1 (hu)
TW (1) TW480174B (hu)
WO (1) WO1996038159A1 (hu)
ZA (1) ZA963810B (hu)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741525A (en) * 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
GB2310375A (en) * 1996-02-21 1997-08-27 Vanessa Clare Mcclafferty Pessaries for treating vaginal infections
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
RO113114B1 (ro) * 1997-08-05 1998-04-30 Rodica Teodorescu Produs eubiotic natural, pentru intretinerea si tratamentul tegumentelor
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
EP0956858B1 (en) * 1998-04-30 2001-10-31 Renata Maria Anna Cavaliere Vesely Pharmaceutical compositions containing Lactobacillus brevis and Lactobacillus salivarius for treatment of vaginal infections
KR20010101171A (ko) * 1998-12-11 2001-11-14 추후기재 비뇨생식기 감염의 치료 및 예방을 위한 락토바실러스의경구 투여
US6706287B2 (en) * 2001-05-15 2004-03-16 Kibow Biotech Inc. Prebiotic and probiotic compositions and methods for their use in gut-based therapies
US7998470B2 (en) * 1999-04-30 2011-08-16 Kibow Biotech, Inc. Compositions and methods improving renal function
US20040197352A1 (en) * 1999-04-30 2004-10-07 Natarajan Ranganathan Methods of improving or augmenting kidney function
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
US20020044926A1 (en) * 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
EP1110555A1 (fr) * 1999-12-22 2001-06-27 Societe Des Produits Nestle S.A. Agent anti-adhesion de la flore pathogene de la peau
US6767537B2 (en) 2000-05-26 2004-07-27 Phil Arnold Nicolay Composition and method for the treatment of sinusitis
US7269735B2 (en) * 2000-08-28 2007-09-11 Contentgaurd Holdings, Inc. Instance specific digital watermarks
US20030091540A1 (en) * 2001-10-16 2003-05-15 Nawaz Ahmad Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity
EP1319410A1 (en) * 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Use of micro-organisms for a directed delivery of substances to specific parts of the gut
US20050266069A1 (en) * 2002-09-06 2005-12-01 Simmons Donald L Stable probiotic microsphere compositions and their methods of preparation
MXPA06001821A (es) * 2003-08-18 2006-05-31 Bio Balance Corp Una composicion probiotica, liquida, estable, preparacion y aplicaciones de la misma.
US7132102B2 (en) * 2003-08-21 2006-11-07 The United States Of America As Represented By The Secretary Of Agriculture Bacteriocins and novel bacterial strains
EP1675617B1 (en) 2003-09-30 2017-07-26 Kibow Biotech, Inc. Compositions for augmenting kidney function
CN101415389A (zh) * 2003-10-02 2009-04-22 生物平衡公司 干燥的生物治疗性组合物、其用途以及施用装置和方法
US20070009490A1 (en) * 2003-10-02 2007-01-11 Conte Anthony E Dried biotherapeutic composition, uses, and device and methods for administration thereof
IE20030773A1 (en) 2003-10-17 2005-04-20 Teagasc Agric Food Dev Authori Use of probiotic bacteria in the treatment of infection
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050208034A1 (en) * 2004-03-17 2005-09-22 Jordan Lazonia V Natural vaginal yeast infection control
AU2005257033B2 (en) * 2004-06-23 2011-05-12 L'oreal Method and compositions useful for preventing and/or treating sensitive and/or dry skin
US20060003454A1 (en) * 2004-07-02 2006-01-05 Conjugon, Inc. Non-dividing donor cells for gene transfer
BRPI0516437A (pt) * 2004-10-04 2008-09-02 Oreal E Nestec S A L utilização de uma quantidade eficaz de pelo menos um microorganismo, processo de tratamento cosmético, composição cosmética e/ou dermatológica e composição para absorção oral
US20060270040A1 (en) * 2005-05-26 2006-11-30 Conjugon, Inc. Compositions and methods for treating tissue
PL1885383T3 (pl) 2005-05-31 2017-06-30 Iams Europe B.V. Kocie probiotyczne bifidobakterie
EP2261323A1 (en) 2005-05-31 2010-12-15 The Iams Company Feline probiotic lactobacilli
US8784851B2 (en) 2005-07-28 2014-07-22 University Of Hull Topical formulations containing sporopollenin
FR2889057B1 (fr) * 2005-08-01 2008-07-18 Oreal Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches
CN100382792C (zh) * 2005-09-12 2008-04-23 大连三仪动物药品有限公司 药用水溶性微胶囊及生产方法
US20070166295A1 (en) * 2006-01-13 2007-07-19 Vet Solutions L.P. Anti-Diarrhea Preparations for Small Domestic Animals
US20070286813A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
ATE433675T1 (de) * 2006-10-13 2009-07-15 Gervais Danone Sa Neue zusammensetzung zur verbesserung des hautzustandes und verfahren zu ihrer herstellung
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
ES2322116B1 (es) 2007-03-12 2010-03-29 Consejo Superior Investig. Cientificas Microorganismo productor de anticuerpos, elementos necesarios para su obtencion, anticuerpos asi producidos, composiciones terapeuticas y sus aplicaciones.
FR2919501B1 (fr) * 2007-08-02 2010-12-31 Oreal Utilisation d'hesperidine ou de l'un de ses derives pour la prevention et/ou le traitement des peaux relachees
FR2920304B1 (fr) 2007-09-04 2010-06-25 Oreal Utilisation cosmetique de lysat bifidobacterium species pour le traitement de la secheresse.
FR2920305B1 (fr) * 2007-09-04 2010-07-30 Oreal Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles.
CN101815502B (zh) * 2007-09-04 2013-10-09 欧莱雅 橙皮苷和微生物的组合在影响皮肤的屏障功能中的用途
US8236297B2 (en) * 2007-10-11 2012-08-07 Kenneth Manzo Method of treating lactose intolerance using genetically engineered bacteria
WO2009123982A2 (en) * 2008-03-31 2009-10-08 Osel, Inc. Transiently buffered lactobacillus preparations and use thereof
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
KR100990765B1 (ko) 2008-06-13 2010-10-29 롯데쇼핑주식회사 락토바실러스 펜토서스 3090의 배양상등액을 함유하는항균제 조성물
GB0812513D0 (en) 2008-07-09 2008-08-13 Univ Hull Delivery vehicle
EP2158916A1 (en) * 2008-08-27 2010-03-03 Ellen Aktiebolag Administration unit comprising lactic acid bacteria
FR2942719B1 (fr) * 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
EP2243487A1 (en) 2009-04-23 2010-10-27 Actogenix N.V. Enteric coated formulation
CL2009001505A1 (es) * 2009-07-01 2009-09-25 Univ Concepcion Formulacion prebiotica de uso topico que comprende microesferas con composicion matricial a base de gelatina natural reticulada y una cepa probiotica viable de lactobacillus spp; proceso para generar dicha formulacion; uso de dicha formulacion para tratar lesiones de la piel.
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
GB0916335D0 (en) * 2009-09-17 2009-10-28 Martin W J Medicaments
US20110070334A1 (en) 2009-09-20 2011-03-24 Nagendra Rangavajla Probiotic Stabilization
PT2338476E (pt) * 2009-12-02 2012-09-28 Bettina Heil Supositório para administração rectal, vaginal ou uretral contendo um probiótico, um antibiótico e um ácido adiposo insaturado não esterificado
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
NL2004520C2 (en) * 2010-04-07 2011-10-11 Univ Delft Tech HEALING AGENT FOR SELF-HEALING CEMENTIOUS MATERIALS.
CA2825473C (en) 2011-01-25 2021-02-16 Austrianova Singapore Pte Ltd. Protection of microbial cells from acidic degradation
DE102011009798B4 (de) 2011-01-31 2015-03-05 Merz Pharma Gmbh & Co. Kgaa Balneologische lipidhaltige probiotische Zubereitungen für kosmetische / dermatologische / medizinische Anwendungen
US10588857B2 (en) 2012-03-29 2020-03-17 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
CN102613458B (zh) * 2012-04-16 2013-12-18 广东仙乐制药有限公司 一种益生菌软胶囊及其制备方法
ES2792106T3 (es) 2012-05-18 2020-11-10 Genome Res Ltd Métodos y grupos
FR2999601B1 (fr) 2012-12-17 2015-01-30 Urgo Lab Methode pour prevenir et/ou traiter les infections, colonisations ou maladies liees a staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis et/ou bacteroides fragilis
BR112015023124A2 (pt) 2013-03-14 2017-07-18 Therabiome Llc liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
KR101640744B1 (ko) 2014-05-07 2016-07-19 일동제약주식회사 고분자 다당 바인더에 컨쥬게이트된 락토바실러스 람노서스 rht-3201, 및 이의 아토피 예방 및 치료 용도
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
US10632157B2 (en) 2016-04-15 2020-04-28 Ascus Biosciences, Inc. Microbial compositions and methods of use for improving fowl production
DK3314007T3 (da) 2015-06-25 2024-04-22 Native Microbials Inc Fremgangsmåder, apparater og systemer til analyse af mikroorganismestammer fra komplekse heterogene miljøer til forudsigelse og identificering af funktionelle forbindelser og interaktioner derimellem og udvælgelse og syntese af mikrobielle ensembler baseret derpå
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
CN108076643B (zh) * 2015-06-29 2021-09-21 辉凌制药公司 用于治疗例如细菌性阴道病的鼠李糖乳杆菌细菌
US9993507B2 (en) 2016-01-07 2018-06-12 Ascus Biosciences, Inc. Methods of improving milk production and compositional characteristics
MX2018012553A (es) 2016-04-15 2019-03-28 Ascus Biosciences Inc Metodos para mejorar la produccion agricola de aves de corral mediante la administracion de consorcios microbianos o cepas purificadas de los mismos.
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3562954A1 (en) 2016-12-28 2019-11-06 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon
WO2018201049A1 (en) 2017-04-28 2018-11-01 Ascus Biosciences, Inc. Methods for supporting grain intensive and/or energy intensive diets in ruminants with a synthetic bioensemble of microbes
AR113371A1 (es) 2017-10-18 2020-04-22 Ascus Biosciences Inc Aumento de la producción de aves de corral mediante la administración de un bioensamblaje sintético de microbios o cepas purificadas de los mismos
RU2744839C1 (ru) * 2020-02-02 2021-03-16 Михаил Викторович Комаров Микроконтейнеры для защиты микроорганизмов, применяемые в сельском хозяйстве

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637297A5 (fr) * 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
US4983163A (en) * 1981-10-09 1991-01-08 Science Research Center, Inc. Method, compositions and articles for prevention and treatment of herpes simplex virus infections
JPS5911177A (ja) * 1982-07-12 1984-01-20 Seikenkai 新規乳酸桿菌
CN1057446C (zh) * 1993-02-02 2000-10-18 西安华誉技术发展有限公司 活性乳酸杆菌胶囊
ZA942302B (en) * 1993-12-03 1995-09-29 Lafor Lab Ltd Viracidal bactericidal and spermicidal vaginal suppository
UA39965C2 (uk) * 1993-12-03 2001-07-16 Лайфор Леборетріз Лтд Вірусоцидний, бактерицидний та руйнуючий сперматозоїди вагінальний засіб і вагінальний супозиторій ( варіанти )

Also Published As

Publication number Publication date
DE69634171D1 (de) 2005-02-17
KR19990022220A (ko) 1999-03-25
HUP9900682A3 (en) 2000-10-30
IL118304A0 (en) 1996-09-12
JPH11506451A (ja) 1999-06-08
US5633012A (en) 1997-05-27
US5635202A (en) 1997-06-03
CA2222642A1 (en) 1996-12-05
AR002754A1 (es) 1998-04-29
WO1996038159A1 (en) 1996-12-05
EP0828499A1 (en) 1998-03-18
KR100478326B1 (ko) 2005-07-28
AU702799B2 (en) 1999-03-04
CN1100546C (zh) 2003-02-05
DE69634171T2 (de) 2006-01-19
EP0828499B1 (en) 2005-01-12
CN1192151A (zh) 1998-09-02
PL323748A1 (en) 1998-04-14
TW480174B (en) 2002-03-21
ATE286737T1 (de) 2005-01-15
EA199700437A1 (ru) 1998-08-27
CA2222642C (en) 2004-09-07
NZ309456A (en) 2001-02-23
EA000412B1 (ru) 1999-06-24
US5614209B1 (en) 1998-08-04
AU5963196A (en) 1996-12-18
BR9609460A (pt) 1999-03-02
ZA963810B (en) 1997-01-03
IL118304A (en) 2000-08-13
MY120501A (en) 2005-11-30
US5733568A (en) 1998-03-31
MX9709318A (es) 1998-02-28
US5614209A (en) 1997-03-25

Similar Documents

Publication Publication Date Title
HUP9900682A2 (hu) Mikrokapszulázott tejsavbaktérium orvosi alkalmazásra
YU48583B (sh) Postupak za pripremanje formulacije u obliku pilule za oralno davanje
MXPA97009318A (en) Lactobacilos micro-encapsulados para aplicacionesmedi
CA2186039A1 (en) New oral pharmaceutical dosage form
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
DK0495349T3 (da) Aktivmiddelpræparat til oral indgivelse, især til drøvtyggere
BG100933A (en) Polymer coated tablets comprising amoxycilin and clavulanate
CA2169087A1 (en) Silicone grafted thermoplastic elastomeric copolymers and hair and skin care compositions containing the same
JP2002512615A (ja) 微生物感染を予防または制御するための共生Ｂａｃｉｌｌｕｓ芽胞の局所的使用
FI945621A0 (fi) Säädetysti vapauttava valmiste
DK0806941T3 (da) Liposomalt antibakterielt præparat med lav fasthed
Leyden et al. Erythromycin 2% gel in comparison with clindamycin phosphate 1% solution in acne vulgaris
EE03597B1 (et) Farmatseutiline kompositsioon, mis sisaldab Lactobacillus plantarum'it ja arginiini
Braathen Topical clindamycin versus oral tetracycline and placebo in acne vulgaris
MD1504F2 (ro) Aplicare a dimeticonei în calitate de ingredient activ în compoziţie farmaceutică pentru tratamentul aftelor şi stomatitelor şi compoziţie farmaceutică conţinând dimeticonă
WO2000016786A3 (en) Oxihumic acid and its use in the treatment of various conditions
Baptista et al. Contact dermatitis from sodium fusidate.
IE853206L (en) Use of aminosulfonic acids in treatment of inflammatory¹conditions
Pakrooh Comparative trial of fucidin ointment and fucidin cream in skin sepsis
CA2259270A1 (en) Pharmaceutical preparation containing nimesulide for oral administration
TH30150B (th) แลคโตแบซิลไลในรูปไมโครเอนแคปซูลเลทด์เพื่อการประยุกต์ใช้งานทางการแพทย์
JPH0426416Y2 (hu)
Shanks et al. Comparison of oral erythromycin ethylsuccinate and clavulanate-potentiated amoxicillin in the treatment of acute respiratory tract infections
Santaella et al. A multicenter, randomized, double-blind study comparing once-daily bedtime administration of famotidine and ranitidine in the short-term treatment of active duodenal ulcer
Vazquez New vitamin B-12 gel, instead of injection

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees